title: The toll-like receptor 3 ligand, poly(I:C), improves immunosuppressive function and therapeutic effect of mesenchymal stem cells on sepsis via inhibiting MiR-143.
abstract: Mesenchymal stem cells (MSCs) are attractive candidates for clinical therapeutic applications. Recent studies indicate MSCs express active Toll-like receptors (TLRs), but their effect on MSCs and the underlying mechanisms remain unclear. In this study, we found that, after treating human umbilical cord MSCs with various TLR ligands, only TLR3 ligand, poly(I:C), could significantly increase the expression of cyclooxygenase-2 (COX-2). Furthermore, poly(I:C) could enhance MSCs' anti-inflammatory effect on macrophages. Next, we focused on the regulatory roles of microRNAs (miRNAs) in the process of poly(I:C) activating MSCs. Our experiments indicated that miR-143 expression was significantly decreased in MSCs with poly(I:C) treatment, and the expression level of miR-143 could regulate the effect of poly(I:C) on MSCs' immunosuppressive function. Subsequent results showed that the reporter genes with putative miR-143 binding sites from the transforming growth factor-β-activated kinase-1 (TAK1) and COX-2 3' untranslated regions were downregulated in the presence of miR-143. In addition, mRNA and protein expression of TAK1 and COX-2 in MSCs was also downregulated with miR-143 overexpression, suggesting that TAK1 and COX-2 are target genes of miR-143 in MSCs. Consistent with miR-143 overexpression, TAK1 interference also attenuated MSCs' immunosuppressive function enhanced by poly(I:C). Additionally, it was shown that TLR3-activated MSCs could improve survival in cecal ligation and puncture (CLP)-induced sepsis, while miR-143 overexpression reduced the effectiveness of this therapy. These results proved that poly(I:C) improved the immunosuppressive abilities of MSCs, revealed the regulatory role of miRNAs in the process, and may provide an opportunity for potential novel therapies for sepsis.
authors.affiliation: The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing, China.
authors.forename: Xiaoyin
authors.initials: X
authors.lastname: Zhao
authors.forename: Dan
authors.initials: D
authors.lastname: Liu
authors.forename: Wei
authors.initials: W
authors.lastname: Gong
authors.forename: Guangfeng
authors.initials: G
authors.lastname: Zhao
authors.forename: Liu
authors.initials: L
authors.lastname: Liu
authors.forename: Liu
authors.initials: L
authors.lastname: Yang
authors.forename: Yayi
authors.initials: Y
authors.lastname: Hou
mesh_terms: D002454:Cell Differentiation; D051546:Cyclooxygenase 2 / Q000378:metabolism; D006801:Humans; D007165:Immunosuppression Therapy; D008264:Macrophages / Q000378:metabolism; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000378:metabolism*; D035683:MicroRNAs; D011070:Poly I-C / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000096:biosynthesis; D018805:Sepsis / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D051196:Toll-Like Receptor 3 / Q000235:genetics* / Q000378:metabolism; D014470:Umbilical Cord / Q000166:cytology
chemical_list: D035683:MicroRNAs; C532884:MIRN143 microRNA, mouse; D012333:RNA, Messenger; D051196:Toll-Like Receptor 3; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011070:Poly I-C
keywords: Mesenchymal stem cells; MiR-143; Sepsis; Toll-like receptor 3